![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-3.00 | -0.27% | 1,122.00 | 1,125.50 | 1,126.50 | 1,132.00 | 1,121.00 | 1,123.00 | 3,601,342 | 16:35:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Ortho,prosth,surg Appl,suply | 5.55B | 263M | 0.3008 | 37.42 | 9.84B |
Date | Subject | Author | Discuss |
---|---|---|---|
09/6/2021 12:16 | Credit Suisse upgraded shares of artificial hip and knee maker Smith & Nephew on Wednesday to 'outperform' from 'neutral', lifting the price target to 1,805p from 1,560p as it pointed to "underappreciated growth drivers".The bank argued that S&N is an underappreciated elective surgery recovery play in the near term and that investors underestimate the combined power of recently-acquired growth drivers with corresponding return leverage mid-term.It upped its FY21-23 sales/adjusted earnings per share estimates by an average 2%/6%, leaving it 3%/5% above Bloomberg consensus."As the drivers become clearer gaining the confidence of investors, we expect Smith & Nephew stock to reverse its material underperformance over the past 12 months," Credit Suisse said.The bank noted that since late 2017, Smith & Nephew has bought several bolt-on technologies, committing close to $1.6bn, and with associated negative M&A effects on trading margin of around 150 basis points for FY21."We deep-dived into the potential for the new technologies," it said. "We believe the Wound Biologics/Sports Medicine/Extremities | ![]() 1nf3rn0 | |
09/6/2021 09:49 | CREDIT SUISSE RAISES SMITH & NEPHEW TO 'OUTPERFORM' (NEUTRAL) - TARGET 1,805 (1,560) PENCE | ![]() its the oxman | |
09/6/2021 08:27 | Fall was unjustified, their main markets are virtually back to normal and lots of pent up demand. Perhaps broker highlighting this? | ![]() spoole5 | |
09/6/2021 08:17 | Bouncing back today, any reason? | ![]() its the oxman | |
09/6/2021 08:01 | I was referencing his opinion on pe as a valuation method | ![]() spoole5 | |
08/6/2021 22:13 | Terry holds Stryker, from memory. Not SN as far as I'm aware. | ![]() essentialinvestor | |
08/6/2021 21:43 | Ask terry smith what he thinks of pe | ![]() spoole5 | |
08/6/2021 18:59 | Only 27 X FY 2022 earnings, what's not to like, eh ) | ![]() essentialinvestor | |
08/6/2021 18:44 | Yes US cases are literally down to the hundreds per state. Down 98% from peak 10,000 for the whole of the USA Have done better than UK as using just Pfizer and Moderna (few % J&J) Highly effective US will have a big boom come 4th July Less than a month to go now! | ![]() justiceforthemany | |
08/6/2021 17:16 | Nice entry point under £14 on an all things being equal basis. | ![]() essentialinvestor | |
08/6/2021 17:14 | May retest the 1350 lows. | ![]() spoole5 | |
05/6/2021 08:44 | Needs to climb through c.1600p to break clear of its downward channel from all time high. | ![]() its the oxman | |
19/5/2021 08:38 | The us is virtually back to normal, where this company does most of its business, yet it still languishes | ![]() spoole5 | |
10/5/2021 18:27 | Taken out the most likely scenario. | ![]() spoole5 | |
08/5/2021 22:33 | Steady climb back to 2000p as covid recedes, operations pick up , or we get taken out. | ![]() its the oxman | |
29/4/2021 16:35 | Added today expecting further gains / market catch up , on the back of this well received update. | ![]() its the oxman | |
29/4/2021 07:45 | Looks decent, probably the only covid sensitive stock yet to recover! | ![]() spoole5 | |
29/4/2021 07:36 | Very encouraging trading statement. May well see that target price of £19.85 before too long... | ![]() hubshank | |
21/4/2021 19:21 | Health care stocks have outperformed, due to a positive read across from US medical devices company Intuitive Surgical, which has sent Smith and Nephew shares to two-month highs,” said CMC Markets analyst Michael Hewson. ADVFN Marke report. | ![]() philanderer | |
21/4/2021 15:05 | Humongous rally it is then.... | ![]() timbo_slice | |
21/4/2021 15:02 | Berenberg reiterates buy with a target price of 1,985.0p | ![]() philanderer | |
19/4/2021 16:21 | Must be correctly priced then.... or due a humongous rally.... | ![]() timbo_slice | |
19/4/2021 10:27 | Everything apart from this seems to be pricing in the reopening of economies, even airlines! | ![]() spoole5 | |
06/4/2021 20:48 | Every little helps! US cracking on with their vaccinations too... | ![]() hubshank | |
06/4/2021 14:26 | This is a global organisation, UK a relatively small part of revenue. | ![]() essentialinvestor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions